+

WO2001079144A3 - Fyn kinase as a target for modulation of integrin mediated signal transduction - Google Patents

Fyn kinase as a target for modulation of integrin mediated signal transduction Download PDF

Info

Publication number
WO2001079144A3
WO2001079144A3 PCT/US2001/012039 US0112039W WO0179144A3 WO 2001079144 A3 WO2001079144 A3 WO 2001079144A3 US 0112039 W US0112039 W US 0112039W WO 0179144 A3 WO0179144 A3 WO 0179144A3
Authority
WO
WIPO (PCT)
Prior art keywords
src
gpiiia
phosphatases
family kinases
modulation
Prior art date
Application number
PCT/US2001/012039
Other languages
French (fr)
Other versions
WO2001079144A2 (en
Inventor
Kyra J Cowan
Debbie A Law
David R Phillips
Original Assignee
Cor Therapeutics Inc
Kyra J Cowan
Debbie A Law
David R Phillips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc, Kyra J Cowan, Debbie A Law, David R Phillips filed Critical Cor Therapeutics Inc
Priority to AU2001255349A priority Critical patent/AU2001255349A1/en
Publication of WO2001079144A2 publication Critical patent/WO2001079144A2/en
Publication of WO2001079144A3 publication Critical patent/WO2001079144A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention describes a direct interaction between phosphorylated GPIIIa cytoplasmic domains with 1) src/non-src family kinases and 2) phosphatases. The invention provides methods for identifying agents that block GPIIIa interactions with src/non-scr family kinases and phosphatases, methods of using agents that block GPIIIa interactions with src/non-src family kinases and PIP-1C phosphatases to modulate biological and pathological processes and agents that block GPIIIa mediated binding to src/non-scr family kinases and PIP-1C phosphatases, thereby modulating related GPIIIa mediated signaling.
PCT/US2001/012039 2000-04-14 2001-04-13 Fyn kinase as a target for modulation of integrin mediated signal transduction WO2001079144A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255349A AU2001255349A1 (en) 2000-04-14 2001-04-13 Fyn kinase as a target for modulation of integrin mediated signal transduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19740300P 2000-04-14 2000-04-14
US60/197,403 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001079144A2 WO2001079144A2 (en) 2001-10-25
WO2001079144A3 true WO2001079144A3 (en) 2002-02-28

Family

ID=22729274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012039 WO2001079144A2 (en) 2000-04-14 2001-04-13 Fyn kinase as a target for modulation of integrin mediated signal transduction

Country Status (2)

Country Link
AU (1) AU2001255349A1 (en)
WO (1) WO2001079144A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735334A4 (en) 2004-03-24 2007-09-05 Auckland Uniservices Ltd Set1 proteins and uses therefor
US8057815B2 (en) 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
CA2579547A1 (en) 2004-09-09 2006-03-16 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disease
EP1877427A4 (en) * 2005-04-19 2009-04-29 Auckland Uniservices Ltd Novel peptides and methods for the treatment of inflammatory disorders
WO2008011513A2 (en) * 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
AU2012257602B2 (en) * 2011-05-13 2016-04-28 Electrophoretics Limited Methods and compositions relating to platelet sensitivity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014432A1 (en) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation of integrin-mediated signal transduction
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
WO1998022500A2 (en) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation of interactions between myosin and integrins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
WO1997014432A1 (en) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation of integrin-mediated signal transduction
WO1998022500A2 (en) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation of interactions between myosin and integrins

Also Published As

Publication number Publication date
WO2001079144A2 (en) 2001-10-25
AU2001255349A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
WO2003050295A3 (en) Assays and implements for determining and modulating hsp90 binding activity
WO1999048868A3 (en) Heterocyclic classes of compounds for the modulating tyrosine protein kinase
WO1998007835A3 (en) Crystal structures of a protein tyrosine kinase
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
WO2001064681A3 (en) 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
ATE217865T1 (en) COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
WO2000051628A3 (en) Methods of modulating lipid metabolism and storage
WO2003035615A3 (en) Tyrosine kinase inhibitors
WO2001079144A3 (en) Fyn kinase as a target for modulation of integrin mediated signal transduction
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
WO2001064741A3 (en) Methods for selectively modulating survivin apoptosis pathways
WO1997040379A3 (en) Assays and reagents for identifying modulators of cdc25-mediated mitotic activation
EP1609864A3 (en) Use of neuronal apoptosis inhibitor protein (NAIP)
WO1998022500A3 (en) Modulation of interactions between myosin and integrins
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
DE69628936D1 (en) TEST FOR IDENTIFICATION OF INHIBITORS OF INTERACTION BETWEEN P53 AND DM2 PROTEINS
EP1082415A4 (en) TECHNIQUES AND COMPOSITIONS USED TO MODULATE ANGIOGENESIS USING TYROSINE KINASE SRC PROTEIN
WO1998049317A3 (en) Diagnosis and treatment of phosphatase- 0r kinase-related disorders
WO1999032627A3 (en) The protein tyrosine kinase substrate lat and its use in the identification of (ant)agonists of the kinase
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use
WO1999010741A3 (en) Methods and reagents for identifying modulators of neuronal apoptosis
WO2007019421A3 (en) Regulation of of s6 kinase protein activity and related methods
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载